|

HWK-007 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: HWK-007 anti-PTK7 targeted ADC

Pipeline

Phase 1: 1

Top Sponsors

  • Whitehawk Therapeutics, Inc.1

Indications

  • PROC1
  • Non-squamous EGFR Wt NSCLC1
  • Ovarian Cancer Metastatic Recurrent1
  • Ovarian Cancer Metastatic1
  • Platinum-resistant Ovarian Cancer1

Little Rock, Arkansas1 trial

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

University of Arkansas

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.